For two decades, the opening move against mantle cell lymphoma has been chemotherapy, and the field’s main innovation has been to pile newer drugs on top of it. BeOne Medicines (Nasdaq: ONC) asked a more provocative question: what if you took the chemo out altogether?
On June 30, the company got its answer. The Phase 3 MANGROVE trial hit its primary endpoint, with Brukinsa (zanubrutinib) plus rituximab reducing the risk of progression or death by 43% versus the standard bendamustine-plus-rituximab (BR) regimen in previously untreated patients. The hazard ratio was 0.57 (95% CI, 0.43–0.76; p<0.0001), assessed by independent review, a result that is both statistically emphatic and clinically meaningful. BeOne plans global regulatory submissions in the second half of 2026.
Why this is bigger than a rare disease
MCL is uncommon, roughly 3,300 new U.S. cases a year, so MANGROVE isn’t about a vast new market. It’s about something more durable: real estate. Brukinsa generated $3.9 billion in 2025, up roughly 49% year over year, and a frontline label plants the drug at the start of the treatment journey, where patients stay on therapy the longest and switching costs are highest. For a flagship asset, moving earlier in the line is the single most valuable thing it can do.
It also fits a strategy BeOne has executed with unusual discipline. The company, the renamed BeiGene, has spent years positioning Brukinsa as a “foundational” B-cell backbone rather than a single-indication product. It recently added Beqalzi (sonrotoclax), the first BCL-2 inhibitor approved in relapsed/refractory MCL, in May 2026, and is building fixed-duration Brukinsa–Beqalzi combinations in CLL. MANGROVE is the franchise reaching its logical next rung.
A genuinely patient-friendly design, and that’s not marketing
Here’s where BeOne deserves real credit. Zanubrutinib is a next-generation covalent BTK inhibitor engineered for complete, sustained BTK occupancy with minimal off-target effects. BTK sits just downstream of the B-cell receptor; inhibiting it cuts the survival and proliferation signaling that malignant B cells depend on.
What sets MANGROVE apart is what it leaves out. Patients took zanubrutinib twice daily plus rituximab for six cycles, then continued zanubrutinib alone until progression or intolerance; the control arm received six cycles of BR. The regimen is chemotherapy-free and rituximab maintenance-free, sparing patients roughly two years of infusions. For the older, frailer patients who make up much of the MCL population, many of whom tolerate bendamustine poorly, an effective oral-anchored option that keeps them out of the infusion chair is not a cosmetic perk. It’s the difference between a regimen they can complete and one they can’t.
The honest comparison: a strong number against a strong incumbent
This is the part the topline excitement tends to skip. Frontline MCL already has an approved BTKi regimen. Acalabrutinib (Calquence) plus BR won FDA approval in January 2025 for previously untreated, transplant-ineligible patients, on the ECHO trial, posting a PFS hazard ratio of 0.73 and median PFS of 66.4 versus 49.6 months.
But ECHO and MANGROVE asked different questions. ECHO added a BTKi to chemotherapy and layered on two years of maintenance rituximab. MANGROVE removed the chemo entirely and still beat it. That’s a meaningfully different, and arguably bolder, clinical statement.
It’s tempting to read MANGROVE’s deeper hazard ratio (0.57 vs 0.73) as proof it’s the better regimen. Resist that. The trials differ in design, control-arm chemo exposure, populations, and follow-up; cross-trial comparison here is unreliable, and BeOne hasn’t claimed otherwise.
History also explains why seasoned readers stay measured. Ibrutinib plus BR prolonged PFS in this setting without improving overall survival, likely because of toxicity, and its U.S. MCL indication was withdrawn in April 2023 when confirmatory data fell short. Even ECHO showed no statistically significant survival benefit. In MCL, PFS wins have a stubborn habit of not translating into survival.
What still has to land
BeOne was candid about the asterisk: it reported a strong but not yet statistically significant trend toward improved overall survival. That puts the asset in good company, and in the same suspense, as its predecessors. Median PFS, patient numbers, follow-up, high-risk subgroups (TP53-mutated, blastoid disease), and full safety detail weren’t disclosed and await a medical meeting.
The regulatory route is well-marked. Acalabrutinib earned full approval on ECHO’s PFS, so a PFS-based filing with a hazard ratio this clean is firmly precedented, and the H2 2026 timeline signals BeOne’s confidence in the package. The open questions are durability, how the curves hold and separate over time, and safety in an elderly, comorbid population on continuous BTKi therapy, where cardiovascular events and bleeding remain class issues even for a cleaner second-generation drug.
Adoption is the subtler hurdle. Acalabrutinib plus BR is already in the guidelines and in physicians’ hands, and MANGROVE’s treat-until-progression design runs against the field’s growing appetite for fixed-duration regimens, a tension visible in BeOne’s own fixed-duration CLL program. The chemo-free pitch is compelling, but indefinite dosing carries cumulative toxicity, adherence, and cost trade-offs that rivals will press.
Worth noting: BeOne shares slipped on the news, trading near $286, a sign the PFS win was largely anticipated and that attention has shifted to the survival readout still to come.
Bottom line
MANGROVE is the rare frontline result that is both strategically shrewd and clinically substantive. It validates a genuinely differentiated, chemo-free and maintenance-free regimen, hands frailer patients a more livable option, and extends Brukinsa’s runway exactly where it matters most. BeOne earned this one.
The restraint is simply about what hasn’t been shown yet: survival is unproven, the magnitude can’t be benchmarked across trials, and durability and safety detail are pending. The asset looks approvable. Whether it unseats acalabrutinib plus BR or settles in beside it will come down to the full dataset, and to whether a life without chemo proves as durable as it is appealing.
Takeaway: A clean, well-earned PFS win that pushes Brukinsa to the front of MCL therapy and offers patients a real chemo-free alternative, strong enough to take seriously, with the survival data the one thing standing between a good result and a definitive one.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada